Your institution may have access to this item. Find your institution then sign in to continue.
Title
Single-Chain Diabodies May Target Variants in Both Solid and Liquid Tumors.
Abstract
The article focuses on lab-developed antibodies using a single-chain diabody format can target TP53 or RAS variants in solid tumors and T-cell receptor variants in blood cancers, researchers has reported in study findings published in Science, Science Immunology, and Science Translational Medicine.